title: Effect of albumin on antitumor activity of diarylsulfonylureas.
abstract: Several diarylsulfonylureas (DSU), including Sulofenur (LY186641) and LY181984, have been described that exhibit wide spectrum and high therapeutic activity against murine solid tumors and human tumor xenografts. The mechanism for antitumor activity is poorly understood. Moreover, in vitro cytotoxic activity in serum-containing medium is not predictive of in vivo antitumor activity for DSU. Since DSU are extensively bound to serum albumin (> 99%), we sought to determine the effect of albumin on tumor cytotoxicity. We adapted human CCRF-CEM leukemia and GC3 colon carcinoma cells for growth in UltraCHO serum- and albumin-free medium. In comparisons between normal growth medium (RPMI-1640 with 10% fetal bovine serum) and UltraCHO medium, the unbound fraction of drug correlated better with cytotoxic activity than did the total drug. Tumor cytotoxicity by DSU required > 24 h and was markedly enhanced in UltraCHO medium. For example, LY181984 and Sulofenur had IC50 values of 7.4 and 12.1 micrograms/ml against CCRF-CEM in normal growth medium and 0.6 and 0.2 microgram/ml in UltraCHO. Moreover, DSU with the lowest IC-50s in albumin-free medium displayed the most potent in vivo antitumor activity in the 6C3HED lymphosarcoma. A Sulofenur-resistant CCRF-CEM cell line was developed by culturing the cells for > 20 passages in UltraCHO medium containing LY186641 at 2 micrograms/ml (10X IC-50). This line showed approximately 18-fold resistance to LY186641, but did not show cross-resistance to vinblastine, actinomycin D, or doxorubicin. The albumin-free conditions may be useful for further mechanistic studies on the antitumor action by DSU. Further studies are underway to determine whether DSU structural requirements for cytotoxicity an albumin binding are intrinsically linked.
authors.affiliation: Division of Cancer Research, Lilly Research Laboratories, Indianapolis, IN 46285.
authors.forename: R M
authors.initials: RM
authors.lastname: Schultz
authors.forename: S L
authors.initials: SL
authors.lastname: Andis
authors.forename: J E
authors.initials: JE
authors.lastname: Toth
authors.forename: G B
authors.initials: GB
authors.lastname: Boder
authors.forename: S M
authors.initials: SM
authors.lastname: Rinzel
authors.forename: G B
authors.initials: GB
authors.lastname: Grindey
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D051379:Mice; D008809:Mice, Inbred C3H; D015394:Molecular Structure; D012709:Serum Albumin / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013453:Sulfonylurea Compounds / Q000633:toxicity*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D012709:Serum Albumin; D013453:Sulfonylurea Compounds; C062821:LY 181984; C058179:sulofenur